Abstract |
The convenience to count with a safe and effective pharmacological wealth for atrial fibrillation treatment had conduced, in a way, to a deep depuration of the vast array of antiarrhythmic drugs, keeping only a very restricted number of compounds with a widely proved anti-atrial activity. On the other hand, it had lead to the discovery of the pathophysiological concepts that point to novel therapeutic targets. Within these objectives is that new antiarrhythmic drugs with preferential, even selective, activity on myocardial atrium ion channels had been developed. Among these new antiarrhythmics, dofetilide, and AVE0118, are taken into account. In addition, new possibilities are opened based on the knowledge of the cardioprotective-antiarrhythmic qualities of the opioidergic system.
|
Authors | Gustavo Pastelín Hernández, Pastor Luna Ortíz, Fermín Alejandro Tenorio López, Leonardo del Valle Mondragón |
Journal | Archivos de cardiologia de Mexico
(Arch Cardiol Mex)
2007 Apr-Jun
Vol. 77 Suppl 2
Pg. S2-59-S2-63
ISSN: 1405-9940 [Print] Mexico |
Vernacular Title | Nuevos antiarrítmicos en lafibrilación auricular. |
PMID | 17972381
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- AVE 0118
- Anti-Arrhythmia Agents
- Biphenyl Compounds
- Ion Channels
- Phenethylamines
- Potassium Channel Blockers
- Receptors, Opioid
- Sulfonamides
- dofetilide
|
Topics |
- Administration, Oral
- Anti-Arrhythmia Agents
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Atrial Fibrillation
(drug therapy, physiopathology)
- Biphenyl Compounds
(administration & dosage, pharmacology, therapeutic use)
- Electrophysiology
- Heart Atria
(drug effects)
- Humans
- Ion Channels
(drug effects)
- Phenethylamines
(administration & dosage, pharmacology, therapeutic use)
- Potassium Channel Blockers
(administration & dosage, pharmacology, therapeutic use)
- Randomized Controlled Trials as Topic
- Receptors, Opioid
(drug effects)
- Sulfonamides
(administration & dosage, pharmacology, therapeutic use)
- Time Factors
|